Zenidatamab for injection (zanidatamab-hrii) - Effects and efficacy of Ziihera

Zenidatamab for injection (zanidatamab-hrii)-Ziihera is a new bispecific monoclonal antibody mainly used to treat a variety of HER2-positive cancers, including but not limited to breast cancer and biliary tract cancer. HER2 (human epidermal growth factor receptor 2) is a tyrosine kinase receptor expressed on the cell membrane, and its overexpression is closely related to the occurrence and development of various cancers. HER2 plays a crucial role in intracellular signaling, especially in regulating cell proliferation, differentiation, and apoptosis.

The working mechanism of zenidatuzumab is mainly achieved by bindingtwo different sites of HER2: the juxtamembrane domain and the dimerization domain. This dual binding ability allows zenidatumumab to effectively prevent the dimerization of the HER2 receptor, thereby inhibiting the activation of its downstream signaling pathways and blocking the growth signals of tumor cells. In addition, after binding to HER2, the drug can induce receptor internalization and promote tumor cell apoptosis, thereby achieving therapeutic effects.

Clinical studies have shown that zenidatuzumab is significantly more effective inHER2-positive patients than in HER2-negative patients. This discovery highlights the potential use of this drug in the treatment of tumors with abnormal HER2 expression. Although the exposure-response relationship and the time course of pharmacodynamic response of zenidatuzumab are not yet fully understood, existing research results provide support for its clinical application.

The development of zenidatuzumab represents a new direction in anti-HER2 treatment, especially when traditional treatments (such as Herceptin and other small molecule drugs) fail. It not only provides new treatment options for patients, but also provides inspiration for future anti-cancer drug development.

Reference materials:https://go.drugbank.com/drugs/DB15471